Why the study?
Does bezafibrate alter prebeta1-HDL and HDL2b levels in patients with hypertriglyceridemia?
Population
40 subjects: 20 hypertriglyceridemics (triglycerides >2.26 mmol/L) and 20 sex-matched normolipidemics
Comparison
Bezafibrate 400 mg daily for 4 weeks vs Baseline values (pre-treatment)
Design
Cohort
Follow-up
4 weeks
Authors
Loading...
Bezafibrate-associated HDL remodeling should not yet change practice in hypertriglyceridemia; leaves open contribution to cardiovascular protection.
Does bezafibrate alter prebeta1-HDL and HDL2b levels in patients with hypertriglyceridemia?
Bezafibrate increases prebeta1-HDL and decreases HDL2b, likely via increased hepatic lipase activity, which may contribute to its antiatherogenic effects.
Miida et al. (2000) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: